NASDAQ · ONCT
Healthcare · Biotechnology
$0.53
Down-$0.17 (-24.12%)
Updated Sep 17, 2026, 6:31 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ONCT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ONCT.
ONCT research
Company profile and research snapshot.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 12, 2024 | Brookline Capital | Hold | — |
| Sep 12, 2024 | Northland Capital Markets | Market Perform | — |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2024 | HC Wainwright & Co. | Buy | — |
| May 31, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · May 9, 2024
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 8, 2024
Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewswire Inc. · May 1, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management.
Zacks Investment Research · Apr 25, 2024
Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONCT.
No results
No recent SID articles mention ONCT.
